Drug intelligence / Profile preview

KB303

Development stage: Preclinical
Lead developer: Jeune Aesthetics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intradermal

Overview

**KB303** is a preclinical gene therapy developed by Jeune Aesthetics using a proprietary skin-optimized gene delivery platform to address aging and photo-damaged skin. It delivers the **ELN gene** (encoding elastin), a critical structural protein that declines with age, to stimulate dermal fibroblasts to naturally replenish elastin, improving skin elasticity, reducing wrinkles, and reversing age-related skin changes. Originally spun out from Krystal Biotech, Jeune focuses on aesthetic indications like skin aging, with KB303 positioned early in their pipeline alongside collagen-targeted candidates.

Targets

ELN (Elastin)

Beyond the preview

Go deeper on KB303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KB303.

Explore the full profile